格隆汇11月5日|恒瑞医药与美国Kailera Therapeutics公司公布的GLP-1/GIP双受体激动剂HRS9531注射液Ⅲ期临床试验(GEMINI-1)数据显示,治疗48周后,HRS9531各剂量组平均减重百分比均显著优于安慰剂组,其中6 mg组平均减重19.2%。此前Ⅱ期临床试验结果显示,8 mg组平均减重23.6%。恒瑞医药已递交新药上市申请,Kailera计划年底前启动全球Ⅲ期...
Source Link格隆汇11月5日|恒瑞医药与美国Kailera Therapeutics公司公布的GLP-1/GIP双受体激动剂HRS9531注射液Ⅲ期临床试验(GEMINI-1)数据显示,治疗48周后,HRS9531各剂量组平均减重百分比均显著优于安慰剂组,其中6 mg组平均减重19.2%。此前Ⅱ期临床试验结果显示,8 mg组平均减重23.6%。恒瑞医药已递交新药上市申请,Kailera计划年底前启动全球Ⅲ期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.